report, examined my revisions, and recommended rejection of the subcommittee's critical report, a lead industry executive wrote to members of the subcommittee on his own and attempted to elicit unfavorable comments on my work.

This kind of activity and the misrepresentation of EPA's position, repeated many times in many settings, has led me to the conclusion that the lead industry and its representatives do not qualify as disinterested scientists.

The central question clearly is not whether my 12-year-old study has flaws; of course it does. But the work has survived what I believe to be among the most thorough scrutinies in environmental health and has been judged by many critics as valid. In attempting to make their case the lead industry has ignored the animal data, the 17 studies of children published since my 1979 paper (all showing effects at lower lead levels than I did), and three published meta-analvses of cross-sectional low-level lead studies (2) which show a strongly significant lead effect. It is a defensible proposition that there are no independently funded researchers of lead effects in children who do not believe that lead at low doses is neurotoxic. If there are, they have neither published their comments in the open literature nor have they given them at meetings of scientific societies.

I would have ignored this chronic relapsing industrial food fight had it not occurred at a time when critical public health decisions are in the balance. The Public Health Service, having recognized that childhood lead poisoning is one of the most serious problems for the children in the United States and that it is an eradicable disease, has drafted a Strategic Plan that, if implemented, will begin the process of breaking the exposure link by getting lead out of the environment before it finds its way into children's brains. It now appears that the White House has decided that increased federal participation will not take place (7). This would be a tragedy and cannot be allowed to happen without a complete discussion of the costs to our society.

HERBERT L. NEEDLEMAN Professor of Psychiatry and Pediatrics, University of Pittsburgh, School of Medicine, 305 Iroquois Building, Pittsburgh, PA 15213

REFERENCES

- 1. R. Rabin, Am. J. Publ. Health 79, 1668 (1989).
- H. L. Needleman and G. Gatsonis, J. Am. Med. Assoc. 263, 673 (1990); J. Schwartz, H. Pitcher, R. Levin, B. Ostro, A. L. Nichols, Costs and Benefits of Reducing Lead in Gasoline: Final Regulatory Analysis

(U.S. Environmental Protection Agency/OPA, Washington, DC, 1985); H. L. Needleman and D. Bellinger, in *Lead Exposure and Child Development: An International Assessment*, M. A. Smith, L. D. Grant, A. I. Sors, Eds. (Kluwer Academic for the Commission of the European Communities and the U.S. Environmental Protection Agency, Boston, MA, 1989).

- H. L. Needleman et al., N. Engl. J. Med. 300, 689 (1979).
- Air Quality Criteria for Lead (EPA 600/8-831/028df, U.S. Environmental Protection Agency, Research Triangle Park, NC, June 1986).
- "Air quality criteria for lead. Draft document for external review" (EPA 600/8-83-028A, U.S. Environmental Protection Agency, Washington, DC, October 1983).
- "Minutes, Clean Air Scientific Advisory Committee (CASAC)" (Science Advisory Board, U.S. Environmental Protection Agency, Washington, DC, 27 April 1984).
- 7. P. J. Hilts, New York Times, 24 August 1991, p. 14.

Palca's piece on the effects of low-level lead on IO leaves me bewildered. The only recourse in case of doubt is replication. Here \$63 million was involved in one settlement. It appears that a British study is at odds with the conclusions of Needleman et al. One would think that there would be honest scientists who could be interested in resolving a matter so important to both health and the economy. It seems reasonable that a new study could be carried out for less than the cost of further compliance with unreasonably low levels, if, indeed, the levels set by EPA are unreasonably low. Yet, all we hear is denial, controversy, and name-calling. Is a resolution of important scientific issues through careful replication of the valid features of Needleman et al.'s study impossible in this country? Impractical? Must we continue in doubt?

> JOHN R. PIERCE Center for Computer Research in Music and Acoustics, Stanford University, Stanford, CA 94305

Palca's excellent article touches on one of the sorriest and most vexing aspects of modern toxicology, namely the large number of disputed and contradictory results. In many cases, the normal self-cleansing mechanism in science is short-circuited when regulatory agencies pick disputed results as their favorites. All of this has contributed to the unfortunate image of toxicology as a discipline where any kind of result can be obtained and published and any kind of toxicological view can be heard in the courts. Only sunlight and better science will ultimately resolve this and other controversies.

> GERHARD STÖHRER Washington Institute for Values in Public Policy, Suite 300, 1015 18th Street NW, Washington, DC 20036

Cancer Risk and Behavior Change

I couldn't agree more with the sentiments of many of the researchers interviewed for Jean Marx's Special Report "Zeroing in on individual cancer risk" (9 Aug., p. 612): prevention (and early diagnosis) is the way to go! I find it surprising, however, that the most effective prevention technique we have-behavior change-is scarcely mentioned. Stopping smoking, reducing dietary fat, getting more exercise, taking precautions against too much sun exposure, and following recommended screening procedures, such as having annual mammographies, pap smears, and skin examinations (where appropriate), would go a long way toward reducing cancer incidence and mortality in this country.

Molecular approaches do indeed appear to hold greater promise for identifying which individuals are at risk than do currently available epidemiological methods. But once individuals have been "identified," many may elect to change their behavior rather than use such "ultimate" remedies as chemoprevention, which almost certainly would entail nonnegligible risks of potentially serious side effects. As far as I know, no study has yet shown that changing behavior to reduce the risk of cancer has serious physiological side effects.

> JOSEPH S. ROSSI Cancer Prevention Research Center, University of Rhode Island, Kingston, RI 02881–0808

Electrochemical Sensor: Prior Concept

In our report of 3 May 1991, "Molecular self-assembly of two-terminal, voltammetric microsensors with internal reference" (p. 1991) (1), we described a pH microsensor with detection based on measurement of the potential difference between cyclic voltammetric peaks for two electrode-confined redox reagents: a ferrocenyl alkyl thiol with a pH-insensitive redox potential and a hydroquinone alkyl thiol with a pH-sensitive redox potential. We regret that at the time of publication we were unaware of an existing paper by I. Rubinstein (2) that had previously demonstrated voltammetric pH sensing with detection based on the peak potential difference between two electrodeconfined redox couples, and we wish to credit Rubinstein with priority for this concept. He also mentioned that his systems "are ideal candidates for miniaturization," that a "full voltammetric" operating mode "requires a two- (rather than three-) electrode assembly, which translates into simpler construction and application," and that

SIGNAL TRANSDUCTION RESEARCHERS Try our user-friendly prices

Thapsigargin, 99+%	1mg 5mg 10mg 25mg	\$35.40 \$117.75 \$209.10 \$465.00	Okadaic Ac	id, 98+%	100µg 300µg 1mg 5mg	\$52.20 \$135.00 \$426.00 \$1870.00
Calyculin A, 98+%	50μg 100μg 300μg 1mg	\$82.30 \$138.80 \$397.00 \$1290.00	1-Nor-okada (Negative contro	aone, 98+% I for Okadaic Acid)	50μg 100μg 300μg 1mg	\$98.80 \$182.60 \$477.00 \$1515.00
Phorbol 12-Myristate 13-Acetate (PMA), 99+%	1mg 5mg 25mg	\$12.65 \$35.30 \$123.50	4α-Phorbol 13-Acetate, (Negative contro	12-Myristate 99+% I for PMA)	1mg 5mg 25mg	\$23.65 \$69.85 \$317.80
(ɒ)-Inositol 1,4,5-trisphosphate K ₆ -salt, 99+%	•, 1mg 5mg 10mg	\$26.70 \$121.40 \$231.00	Resiniferato	oxin, 99+%	1mg 5mg 10mg	\$47.50 \$176.00 \$332.00
Substantial additional discounts are available for larger quantities. Call, write, or fax for a free catalog/handbook and prices: LC Services Corp. 165 New Boston Street Woburn, MA 01801 USA Tel: (617) 938-1700 Fax: (617) 938-5420			Overseas us GERMANY: SWITZERLAND: JAPAN: U.K.:	 Isers, please contact your nearest distributor: BIOTREND Chemikalien GmbH, Köln Tel: 0221-497 20 34 Fax: 0221-49 63 41 ANAWA Trading SA, Wangen Tel: 01/833 05 55 Fax: 01/833 05 75 Funakoshi Pharmaceutical Co., Ltd., Tokyo Tel: 81-3-293-2352 Fax: 81-3-295-5545 Scientific Marketing Associates, Barnet, Herts. Tel: 081-447 1159 Fax: 081-447 1162 		

Circle No. 255 on Readers' Service Card

Whitesides, M. S. Wrighton, Science 252, 688

(1991). 2. I. Rubinstein, Anal. Chem. 56, 1135 (1984).

2. I. Rubinstein, Anal. Chem. 50, 1135 (1984).

the "use of automatic peak detectors will improve accuracy." Our work demonstrated to our knowledge for the first time, the miniaturization of such a system, its operation in a two-terminal mode, and its use with derivative voltammetry to locate current peaks. Additionally, we elaborated on the requirements of a two-terminal system, we demonstrated the utility of molecular selfassembly techniques for modifying electrodes to be used in these systems, and we demonstrated the utility of such an electrode for measuring acidity in extremely acidic media. JAMES J. HICKMAN

> DAVID OFER Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139 PAUL E. LAIBINIS GEORGE M. WHITESIDES Department of Chemistry, Harvard University, Cambridge, MA 02138 MARK S. WRIGHTON Department of Chemistry, Massachusetts Institute of Technology Cambridge, MA 02139

REFERENCES

1. J. J. Hickman, D. Ofer, P. E. Laibinis, G. M.

Birds Are Birds

Many of us in the zoological community are still reeling from the news that the birds are extant members of the Dinosauria. Imagine our consternation, then, to learn from the article "The brain as 'sexual organ'" (News & Comment, 30 Aug., p. 957) that they have been moved into the Mammalia . Is this one more example of the breathtaking pace of change in systematics wrought by the adoption of cladistic methods?

> MATTHEW H. GREENSTONE Biological Control of Insects Research Laboratory, Agricultural Research Service, U.S. Department of Agriculture, Post Office Box 7629, Columbia, MO 65205

Response: Even the bird-brained editors at *Science* know birds are not mammals, but the mistake was a result of an editing error late in the production process and we are willing to eat a little crow.—Eds.

Erratum: Shirley Malcom, in her editorial "Plugging the pipeline" (18 Oct., p. 353) mentions the AAAS Mentor Award and directs readers to page 387 of that issue. Because of a printer's error, a Call for Nominations for the Mentor Award did not appear on page 387 and appears instead in this issue (25 Oct., p. 587).

Correction

In the Research News article "A 'mitey' theory for gene jumping" (6 Sept., p. 1093), Jean Marx erred when she wrote that the groups of Marilyn A. Houck and Margaret G. Kidwell (Reports, 6 Sept., p. 1125) focused on Proctolaelaps regalis as a possible carrier of P elements among Drosophila species by a "process of elimination." Viruses were not screened for P elements during the study, as implied, nor were any other organisms. Rather, the work was initiated by acarologist Houck (then on the faculty of the University of Arizona), who was aware of P element history from conversations with the Kidwell lab. Houck and Ken Peterson, a postdoc in the Kidwell lab, then initiated the Southern blot analysis that pointed to the presence of P element DNA in P. regalis, and Jonathan Clark, a postdoc at Arizona's Center for Insect Science, significantly extended the work through the application of polymerase chain reaction. Their data do not exclude the possibility of viral participation in the system, however.—Ēds.